Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study

(2022) Nicolas Margot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

(2022) Sorana Segal-Maurer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients

(2020) Anne-Geneviève Marcelin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

(2020) Michael Kozal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical targeting of HIV capsid protein with a long-acting small molecule

(2020) John O. Link et al.   NATURE

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes

(2020) Nicolas Margot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir

(2018) Max Lataillade et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks

(2018) Nicolas Margot et al.   JOURNAL OF CLINICAL VIROLOGY

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

(2018) Brinda Emu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

(2008) J. M. Jacobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY